$CNC · CENTENE CORP
Centene reported Q3 FY2026 results: GAAP net loss of $71M ($0.14/share) on $50.65B in total revenue (+1.9% YoY). Adjusted EPS was $0.58, up from $0.50 a year ago, but the quarter included $276M in severance costs tied to enterprise optimization and contract exits. The HBR (medical costs/premium revenue) held at 92.7%. Operating loss was $307M.
- GAAP net loss of $71M vs. a $6.63B loss in Q3 2025, which included a $6.72B goodwill impairment.
- Adjusted EPS of $0.58 beat the prior-year $0.50, but included $276M in severance costs from enterprise optimization and contract exits.
- Revenue rose 1.9% YoY to $50.65B; premium and service revenue grew just 0.5% to $45.1B.
- Medical costs consumed 92.7% of premium revenue ($41.1B on $44.4B), up from 92.7% a year ago — flat but elevated.
- Operating loss of $307M reflects $276M severance, $161M amortization, and $35M in optimization vendor costs.
Extended-hours trading shows CNC at $66.00, down 3.04% from the $68.07 regular close. The GAAP loss and heavy severance-driven cost structure are weighing on sentiment despite the adjusted EPS beat.
A $33B managed-care giant reporting a GAAP loss while burning $276M in a single quarter on severance raises questions about the cost and duration of its turnaround.
Centene's flat premium revenue growth and elevated medical cost ratio mirror sector-wide Medicaid managed-care pressure. Peers like Molina and Elevance face similar utilization and redetermination headwinds.
Enterprise optimization severance of $276M in Q3 alone signals ongoing restructuring risk; medical cost ratio remains elevated at ~92.7% with no margin improvement. The filing flags rate cuts, insufficient rate changes, and eAPTC renewal uncertainty as forward risks.